Science is in the midst of a reproducibility crisis and the integration of artificial intelligence into scientific research has only compounded the problem; yet could the technology hold the solution to its own problems?[Formula: see text].

Developments in stem-cell technology have presented researchers with a powerful method with which to examine why things go wrong in early embryonic development, yet with this advance in research ability comes a polarizing ethical dilemma.

Future Drug DiscoveryVol. 2, No. 1 ForewordOpen AccessWelcome to Volume 2 of Future Drug DiscoveryFrancesca Lake & Jennifer StraitonFrancesca Lake *Author for correspondence: E-mail Address: f.lake@future-science.comhttps://orcid.org/0000-0002-7844-6518Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UK & Jennifer StraitonFuture Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UKPublished Online:5 Feb 2020https://doi.org/10.4155/fdd-2019-0036AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit Happy New Year and welcome to Volume 2 of Future Drug Discovery. With 2019 seeing the launch of the journal, it was an exciting year for the Future Drug Discovery team and, in this Foreword, we discuss our highlights and look forward to what is coming in 2020.Content highlights from 2019Future Drug Discovery publishes quarterly issues and many of our issues carry a themed section surrounding a topic of high interest to the drug discovery community. In 2019, we covered the exciting topic of artificial intelligence (AI), which saw us speak with a number of experts to discuss AI concepts, such as the computational chemist, and discuss some of the challenges the AI field faces, including ethics and intellectual property [1]. Separate Editorials also saw R Lawrence (Cancer Research UK Manchester Institute, UK), E Begoli (Oak Ridge National Laboratory, TN, USA) and D Kusnezov (US Department of Energy, DC, USA) discuss their takes on the topic [2,3]. Begoli and Kusnezov summed the topic up nicely in their conclusion: "Clearly the process of drug discovery requires improvements, but the opportunities to do so with AI are manifest." Various commentaries, research, review and opinion pieces were also published. One of our content highlights is a commentary from Zhang et al., which looks at the potential held by metal polyphenol nanonetworks for drug delivery [4]. This article has been read over 900 times and currently holds our most-cited spot. Our most-read article thus far is a research article by Kanna et al., which saw the team investigate whether their perlecan-targeted nanoparticles could improve drug delivery in triple-negative breast cancer [5].We also published a series of interviews with people from various aspects of the drug discovery field discussing life in their areas, including experts from an independent consultancy, contract research organizations and a start-up in a science incubator. We look forward to continuing this series, as it provides an interesting look into the drug discovery careers landscape.Special issues in 2020The year of 2020 will see us publish a plethora of both general and thematic content. This issue is focused around immuno-oncology and we have upcoming issues on drug-repurposing, anti-microbial resistance and computer-aided drug design. If you would like to discuss ideas for any of these issues, please contact us via email.Maximizing discovery across the globeFuture Drug Discovery utilizes a number of services to help support its researchers and maximize the visibility and impact of work. These include Publons (rewarding peer review), Altmetrics (tracking online discussion of articles, such as via social media or news outlets), Dimensions (tracking citations) and ScienceOpen (disseminating research widely and putting it into context). Download, Dimensions and Altmetrics statistics will be shown on article pages, meaning authors can track the success of their articles. At the time of writing (November 2019), our articles had seen nearly 11,000 full-text readers, which is excellent to see. These readers came from across the globe (Figure 1). Figure 1. Future Drug Discovery readership 2019. Expanding the reach of our articlesWe are particularly proud of our partnership with RxNet [6], a free online resource that covers all aspects of pharma R&D. Members of the site gain access to exclusive additional content that builds upon our open access articles, such as our peek behind the paper interview with author J Bajorath. In this interview, he gave further insight into his paper on a novel computational methodology to evaluate chemical optimization [7].Working with the RxNet Editorial team, we were delighted to release the first edition of our Glossary of Drug Discovery last August [8]. Thanks to the help of our expert panel, we compiled a list of all the key terms used in drug discovery – from abbreviated new drug application to Z' factor – and provided handy definitions for your reference. The full glossary is available online and we also hand out physical copies of the book at relevant conferences, so watch out for our booths.In addition, we continue to utilize the power of social media and share all new work on Twitter in order to insure it reaches the largest audience possible; if you do not already, we welcome you to follow us on Twitter (@fsdrugdiscovery).Conferences in 2020Throughout 2019, we were lucky enough to attend multiple exciting conferences, including AAPS PharmSci 360 (TX, USA, 3–6 November 2019), ELRIG Drug Discovery (Liverpool, UK, 5–6 November 2019) and the 4th Medicinal Chemistry and Protein Degradation Summit (London, UK, 28–29 October 2019). It is always great to be able to meet our readers and authors and hear feedback on the journal.If you have any suggestions for conferences in 2020 you would like to meet us at, please let us know. We will be attending various meetings in 2020 with members of the RxNet team, so be sure to look out for our booth and grab a copy of our glossary if you get the chance.Our Editorial Board & contributorsWe are hugely thankful to our Editorial Board [9] for their help in creating Future Drug Discovery and their contributions thus far. Our board comprises experts from across the globe crossing both academia and industry and will be joined in 2020 by a panel of early career researchers who will work to help us ensure the journal is supporting researchers at all career levels. If you would be interested in joining our Early Career Panel, please get in touch; we would be delighted to hear your input.We would also like to thank all the authors and peer reviewers for their contributions in 2019, without whom Volume 1 would not have been possible – we look forward to working with them again in 2020.ConclusionFollowing a successful launch, we are excited to see the journal grow and gain recognition in the field over the coming years. Our plans for themed issues and a focus on early career research mean we have plenty to keep us busy in 2020, although we value any input you may have. If you have any ideas for the journal, be it an outline for an article or a theme for an issue, we would love to hear it, so please get in touch.Financial & competing interests disclosureF Lake and J Straiton are employees of Future Science Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/References1. Future Science. Future Drug Discovery (2019). www.future-science.com/toc/fdd/1/2 Google Scholar2. Begoli E , Kusnezov D . Artificial intelligence's essential role in the process of drug discovery. Future Drug Discov. 1(2), FDD21 (2019). Link, Google Scholar3. Lawrence R . Now the future, we see our dreams: artificial intelligence in drug discovery. Future Drug Discov. 1(2), FDD22 (2019). Link, Google Scholar4. Zhang X , Parekh G , Guo B et al. Polyphenol and self-assembly: metal polyphenol nanonetwork for drug delivery and pharmaceutical applications. Future Drug Discov. 1(1), FDD7 (2019). Link, Google Scholar5. Khanna V , Kalscheuer S , Kirtane A , Zhang W , Panyam J . Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer. Future Drug Discov. 1(1), FDD8 (2019). Link, Google Scholar6. RxNet (2020). http://www.rx-network.com Google Scholar7. RxNet. A peek behind the paper: compound optimization monitor (COMO) for computational evaluation of lead optimization (2019). www.rx-network.com/users/242132-future-drug-discovery/posts/54812-a-peek-behind-the-paper-compound-optimization-monitor-como-for-computational-evaluation-of-lead-optimization Google Scholar8. Future Science. RxNet glossary of drug discovery (2019). www.future-science.com/doi/10.4155/fdd-2019-0101s Google Scholar9. Future Science. Future Drug Discovery – editorial advisory board (2019). www.future-science.com/journals/fdd/editors Google ScholarFiguresReferencesRelatedDetails Vol. 2, No. 1 Follow us on social media for the latest updates Metrics History Received 28 November 2019 Accepted 28 November 2019 Published online 5 February 2020 Published in print January 2020 Information© 2020 Future Science LtdFinancial & competing interests disclosureF Lake and J Straiton are employees of Future Science Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/PDF download

ConcussionVol. 5, No. 1 ForewordOpen AccessWelcome to Volume 5 of ConcussionKimberley Ndungu, Lauren Pulling & Jennifer StraitonKimberley NdunguFuture Science Group, Unitec House, 2 Albert Place, London, N31QB, UK, Lauren PullingFuture Science Group, Unitec House, 2 Albert Place, London, N31QB, UK & Jennifer Straiton*Author for correspondence: E-mail Address: j.straiton@future-science.comFuture Science Group, Unitec House, 2 Albert Place, London, N31QB, UKPublished Online:6 Feb 2020https://doi.org/10.2217/cnc-2020-0001AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit To all of our readers, Happy New Year and welcome to the first issue of Volume 5 of Concussion. As we celebrate our 5th birthday as a journal, we are proud to maintain our commitment to publishing the key advances in clinical and translational research across this niche, yet fast paced, area of research.In this Foreword, we take a look back at some of our content highlights from 2019, as well as introduce our new resource for concussion researchers: Concussion Zone [1]. We also provide an update regarding the work of our parent, The Drake Foundation [2], on behalf of which the journal is published; looking at the projects they are currently funding in order to help further concussion research.Content highlights of 2019The standard of articles published over the past year has remained at the high quality for which we are known and we would like to thank all of our authors and reviewers, each of whom has worked to ensure that all work follows the highest of standards.Our most read article of the year comes from a research team led by Melissa Hunfalvay of RightEye LLC (MD, USA) and describes their novel eye-tracking tests, which measure both horizontal and vertical saccades to create an objective and quantifiable method of differentiating between severities of traumatic brain injury [3]. An altmetric score of 58 puts this article in the top 5% of all research outputs scored by the metrics system and in the 95th percentile of articles of the same age. A follow-up article from this research group was also published in this issue and we recommend you look out for it.A hot topic of the year has been concussion in school- and college-aged adolescents. First, we had a research article written by Arthur Maerlender et al., reporting on a training model to be given to school personnel that will improve knowledge on how to manage concussion in a student [4]. Based on ten key knowledge competencies, the training method gained positive feedback from those involved in the study, with many reporting the competencies to be informative and useful. For anyone who works in concussion management, this is a key read.Following the theme of concussion in young people, we have another research article, this time with a focus on college students. In this article, the research team, led by Zachary W Bevilacqua (Indiana University, ID, USA), present a new approach to monitor concussed students and determine when they are recovered enough to re-enter the academic setting [5]. This concept, commonly referred to as return-to-learn, has been at the forefront of concussion research and as all student-athletes are first and foremost students, a greater understanding is of vital importance.Our final paper to mention comes from Stanford's (CA, USA) Angela Lumba-Brown and colleagues. In their perspective article, they provide an overview of commonly used post-concussion symptom-rating scales and determine the representation of different subtype-directed symptomatologies [6]. They found that overall, the percentage of symptoms representing each subtype was low, though ocular-motor, vestibular and cervical strain-associated conditions were the least represented. This under-representation of key symptoms marks a clear unmet need in the field of concussion research.Editorial boardTo our Editorial board, we thank you for your continued input, be it in an ambassadorial, advisory or authorship role. Our international board provides valuable assistance and advice that facilitate the publication process; we look forward to working together in the coming year.On this note, if you are interested in joining our advisory board or wish to provide feedback or suggestions for the journal, please do not hesitate to get in touch; we value any and all input that can contribute to the growth and development of the journal.Concussion zoneLaunched in September this year, Concussion Zone [1] is a new community site covering the latest news, expert opinions and insights into concussion and traumatic brain injury. On Concussion Zone you can find content and discussion across hot topics in medical research and practice, sport, medico-legal issues and regulation and guidance.By following channels on the site, such as assessment and rehabilitation, imaging or sports and exercise medicine, you can keep up to date on your specific topics of interest. Further, in the events channel, you can find our Editor's reports from relevant conferences.Registration to Concussion Zone is free and will provide you with exclusive access to editorials, opinion pieces and interviews from experts within the field of traumatic brain injury, plus optional newsletters via email to keep you up to date with the latest research.Some of our top pieces of content since our launch include a news piece following the publication of the highly anticipated FIELD study, which reported that professional football (soccer) players are 3.5-times more likely to die due to dementia and over five-times more likely to die due to Alzheimer's disease [7] and an editorial in which Claire Baker (Imperial College London, UK) discusses how on-board sensors could be utilized to reduce the effect of head trauma and gives insight into the work being conducted in the AutoTRIAGE project [8].If you have any ideas on what you would like to see on Concussion Zone or are interested in writing for the site, then please get in touch.Update from The Drake Foundation2019 was a big year for The Drake Foundation, with the kick-off of several new projects, as well as progress updates from several others.In January came the announcement of a new research study to evaluate concussion in Premier League football (soccer) [9]. The study is being led by Tony Belli and Patrick O'Halloran (both University of Birmingham, UK), with support from the Premier League and funding from the Foundation. Over the 2018/19 and 2019/20 seasons, saliva and urine samples will be collected from players who sustain a head injury, as well as noninjured controls. These samples will then be tested using the Birmingham Concussion Test to examine the potential of microRNAs as biomarkers of brain injury. The hope is that the test could 1 day be used pitch-side, with the potential to assist in return-to-play decisions and concussion diagnoses across sport, the military and other frontline settings.This year has also seen the start of recruitment for the HEADING (Health and Ageing Data IN the Game of football) study [10], which will recruit 300 former elite football (soccer) players in order to examine the link between a history of concussion and heading the ball with neurodegenerative disease and long-term cognitive function.Another exciting new addition to The Drake Foundation's research portfolio was launched in 2019: The Drake Football Study (DFS) [11]. The DFS comes as a result from a groundbreaking collaboration between the Foundation (as founding funders) and FIFPRO, the PFA and football players unions across Europe. Researchers will measure the health of professional footballers; a population that has been shown to be more likely to experience problems with their mental, musculoskeletal, neurocognitive and cardiovascular health. Until now, available evidence has been established principally from cross-sectional studies focusing on a specific health domain in either active or retired players. The DFS is the first prospective cohort study that monitors the health of professional footballers across domains (mental, musculoskeletal, neurocognitive and cardiovascular) before, during and after their retirement out of sport. This will hopefully fill the gaps in our knowledge around the onset and progression of several health conditions, which will help equip clubs and medical teams to support future players both in their careers and throughout retirement.Outside the research funding, in November 2019 was the 4th Annual UK Sports Concussion Research Symposium, this year jointly hosted by The Drake Foundation, Football Association, Rugby Football Union, England and Wales Cricket Board and British Horseracing Authority. This year's symposium marked a significant year in the concussion field, with media attention and public interest in the long-term effects of sports concussions continuing to grow, particularly around the publication of the first results from the FIELD study. It was fantastic to hear progress from speakers in concussion research, sporting bodies and technology development, with talks centering on diagnostic and recognition tools, understanding of recovery and medium and long-term consequences of head injury. For a full rundown of the symposium, take a look at the conference report [12] on Concussion Zone.As always, 2020 looks set to be another busy year, with results and publications expected across a number of the Foundation's projects and the launch of more new initiatives across science, sport and society. For more information and the latest news from The Drake Foundation, visit our website [2].ConclusionOur readers remain central to the success of our journal and we welcome any feedback. Please do not hesitate to contact us with any suggestions for what you would like to see featured or any article proposals of your own. We welcome a wide range of unsolicited article proposals, so please do get in touch for more information.We would like to finish by once again thanking all of the authors and reviewers who helped to make Volume 4 possible; we hope to continue to build on this success and look forward to another great year.Financial & competing interests disclosureK Ndungu, L Pulling and J Straiton are employees of Future Science Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/References1. Concussion Zone. www.concussionzone.comGoogle Scholar2. The Drake Foundation. www.drakefoundation.orgGoogle Scholar3. Hunfalvay M, Roberts C-M, Murray M, Tyagi A, Kelly H, Bolte T. Horizontal and vertical self-paced saccades as a diagnostic marker of traumatic brain injury. Concussion 4(1), CNC60 (2019).Link, Google Scholar4. Maerlender A, Lichtenstein JD, Parent-Nichols J, Higgins K, Reisher P. Concussion competencies: a training model for school-based concussion management. Concussion 4(1), CNC61 (2019).Link, Google Scholar5. Bevilacqua ZW, Kerby ME, Fletcher D et al. Preliminary evidence-based recommendations for return to learn: a novel pilot study tracking concussed college students. Concussion 4(2), CNC63 (2019).Link, Google Scholar6. Lumba-Brown A, Ghajar J, Cornwell J et al. Representation of concussion subtypes in common postconcussion symptom-rating scales. Concussion 4(3), CNC65 (2019).Link, Google Scholar7. Concussion Zone. Football and dementia: former players over five times more likely to die of Alzheimer's, says landmark study (2019). www.concussionzone.com/users/296176-concussion-zone/posts/55049-football-and-dementia-former-players-over-five-times-more-likely-to-die-of-alzheimer-s-says-landmark-studyGoogle Scholar8. Baker C. Smart sensors: predicting traumatic brain injury in road traffic collisions. Concussion Zone, London, UK (2019). www.concussionzone.com/users/318476-claire-baker/posts/56405-smart-sensors-predicting-traumatic-brain-injury-in-road-traffic-collisionsGoogle Scholar9. The Drake Foundation. Premier League footballers participate in new ground-breaking concussion study (2019). www.drakefoundation.org/concussion-premier-league-football/Google Scholar10. The Drake Foundation. HEADING – Health and Ageing Data IN the Game of football (2019). www.drakefoundation.org/the-heading-study/Google Scholar11. The Drake Football Study. www.drakefootballstudy.org/Google Scholar12. Concussion Zone. The 4th Annual UK Sports Concussion Research Symposium: highlights and key takeaways (2019). www.concussionzone.com/users/296176-concussion-zone/posts/57264-the-4th-annual-uk-sports-concussion-research-symposium-highlights-and-key-takeawaysGoogle ScholarFiguresReferencesRelatedDetails Vol. 5, No. 1 Follow us on social media for the latest updates Metrics History Received 16 January 2020 Accepted 16 January 2020 Published online 6 February 2020 Published in print March 2020 Information© 2020 Future Medicine LtdFinancial & competing interests disclosureK Ndungu, L Pulling and J Straiton are employees of Future Science Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/PDF download

[Formula: see text] Known to be a sturdy weapon in a scientist's arsenal, how has the gene editing tool CRISPR been applied in the fight against COVID-19?

CNS OncologyVol. 9, No. 1 ForewordOpen AccessWelcome to Volume 9 of CNS OncologyJennifer StraitonJennifer Straiton*Author for correspondence: E-mail Address: j.straiton@future-science.comFuture Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UKPublished Online:2 Mar 2020https://doi.org/10.2217/cns-2019-0023AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit To all of our readers, Happy New Year and welcome to the first issue of Volume 9 of CNS Oncology. 2020 promises to be an exciting year and we look forward to growing the reach and audience of the journal as we enter the new decade. However, before we start this new period, I would like to look back over the past year and our highlights from 2019.Content highlightsOur most-read article of the year comes from Ugonma Chukwueke and Patrick Wen, both of the Dana-Farber Cancer Institute (MA, USA), and reviews the recommendations of the Response Assessment in Neuro-Oncology (RANO) working groups [1]. Distinct RANO groups have been set up for different tumor and treatment types, each group aiming to develop relevant and reliable criteria that can be implemented by clinicians. This review discusses how the recommendations given by the RANO groups may be applied to the care of patients with different brain tumor types and suggests what is still needed for the guidelines to fully reflect the complex nature of each tumor. For anyone interested in neuro-oncology and CNS oncology management, this is a key read. From Issue 1 of this volume, the article has been cited twice and is already the most-read article ever published in CNS Oncology.Next up, we have a preliminary communication written by David E Piccioni et al. (University of California San Diego, CA, USA), describing their study evaluating whether circulating tumor DNA could facilitate genomic interrogation in patients with primary brain tumors [2]. Contrary to previous studies in this area, the group found that 50% of patients included in the study had detectable circulating tumor DNA, making it a clinically viable option for analysis when identifying genomics-based therapy options.Another 2019 article that has hit our most-read list is an editorial that evaluates the benefits of whole-brain radiation therapy versus stereotactic radiosurgery for the treatment of brain metastases [3]. Written by a group from the City of Hope National Medical Center (CA, USA), the article discusses the shift in clinical practice from using whole-brain radiation therapy to stereotactic radiosurgery and looks to the future of radiation therapy for brain metastases.Finally, we have a set of three articles each discussing the Nativis Voyager®, an investigational therapeutic medical device that is being developed for the treatment of both pediatric and adult glioblastoma. With feasibility studies in both American [4] and Australian [5] populations, the researchers found no adverse events that could lead to the discontinuation of the device, and it demonstrated a benign safety profile. However, as stated in an editorial on the device by Victor Levin (MD Anderson, TX, USA), further studies are needed to determine the full impact of the therapy on overall survival of patients with glioblastoma [6].Editorial boardTo our editorial board, we thank you for your continued input, be it in an ambassadorial, advisory or authorship role. Led by our senior editors Alba Brandes (Azienda USL, Bologna, Italy) and Henry Friedman (Duke University Medical Center, NC, USA), our international board provides valuable assistance and advice that facilitate the publication process; we look forward to working together in the coming year.On this note, if you are interested in joining our editorial board or wish to provide feedback or suggestions for the journal, please do not hesitate to get in touch; we value any and all input that can contribute to the growth and development of the journal.Article outreachTo help further spread the work we publish, we continue to utilize the power of social media and share new work through platforms such as Twitter and LinkedIn to ensure articles can be shared with the largest possible audience; if you do not already, we welcome you to follow us on Twitter (@fsg_cns) or join our oncology group on LinkedIn, Future Science Group Oncology. In using social media, it is our aim to reach all relevant stakeholders in the field of CNS oncology – including researchers, clinicians, charities, patients, academics/educators and patient advocates, just to name a few.Our partnerships with the sites Oncology Central [7] and Neuro Central [8] continue, giving authors the opportunity to put their work on the websites and be seen by its wide readership base. Registration to both sites is free and allows you to keep up to date with the latest developments in cancer or neurology via unparalleled free access to the latest news, opinion, peer-reviewed journal articles, multimedia and exclusive content. A great example of this partnership can be seen in our 'peek behind the paper' interview with Charles Cobb, senior author on one of our Voyager papers. In the interview, hosted on Neuro Central, Cobb gives insight into the inspiration behind the Voyager device and discusses challenges faced in developing it [9].I am also excited to announce our partnership with the Video Journal of Biomedicine [10]. Now, our authors are invited to work with our expert video team to produce a short interview-style video, discussing their research. Our first video interview, featuring author Rimas Lukas (Northwestern University, IL, USA), will be published online soon and will see Lukas discussing his recent article in Issue 3 titled, 'Pleomorphic xanthoastrocytoma: a brief review' [11]. Follow our Twitter, or the Video Journal (@VJofBiomedicine), for updates when this is published.ConclusionOur readers remain central to the success of our journal and we welcome any feedback. Please do not hesitate to contact us with any suggestions for what you would like to see featured or any article proposals of your own. We welcome a wide range of unsolicited article proposals so please do get in touch for more information.I would like to finish by once again thanking all of the authors and reviewers who helped to make Volume 8 possible; we hope to continue to build on this success and look forward to another great year.Financial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/References1. Chukwueke UN , Wen PY . Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 8(1), CNS28 (2019). Link, CAS, Google Scholar2. Piccioni DE , Achrol AS , Kiedrowski LA et al. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 8(2), CNS34 (2019). Link, CAS, Google Scholar3. Shinde A , Akhavan D , Sedrak M , Glaser S , Amini A . Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases. CNS Oncol. 8(1), CNS27 (2019). Link, CAS, Google Scholar4. Cobbs C , McClay E , Duic JP , Nabors LB , Murray DM , Kesari S . An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US. CNS Oncol. 8(1), CNS30 (2019). Link, Google Scholar5. Murphy M , Dowling A , Thien C , Priest E , Murray DM , Kesari S . A feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma in Australia. CNS Oncol. 8(1), CNS31 (2019). Link, CAS, Google Scholar6. Levin VA . How far will the Voyager® take us? CNS Oncol. 8(1), CNS26 (2019). Link, CAS, Google Scholar7. Oncology Central (2019). www.oncology-central.com Google Scholar8. Neuro Central (2019). www.neuro-central.com Google Scholar9. Cobbs C . A peek behind the paper – Charles Cobbs on the Nativis Voyager® for the treatment of glioblastoma. Neuro Central, London, UK (2019). www.neuro-central.com/2019/02/01/a-peek-behind-the-paper-charles-cobbs-on-the-nativis-voyager-for-the-treatment-of-glioblastoma/ Google Scholar10. Video Journal of Biomedicine (2019). www.biomedicine.video Google Scholar11. Shaikh N , Brahmbhatt N , Kruser TJ et al. Pleomorphic xanthoastrocytoma: a brief review. CNS Oncol. 8(3), CNS39 (2019). Link, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 9, No. 1 Follow us on social media for the latest updates Metrics History Received 18 December 2019 Accepted 18 December 2019 Published online 2 March 2020 Published in print March 2020 Information© 2020 Future Medicine LtdFinancial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/PDF download

Lung Cancer ManagementVol. 8, No. 1 ForewordOpen AccessWelcome to Volume 8 of Lung Cancer ManagementJennifer StraitonJennifer Straiton*Author for correspondence: E-mail Address: j.straiton@future-science.com Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UKPublished Online:20 Dec 2018https://doi.org/10.2217/lmt-2018-0015AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit As the new Editor for Lung Cancer Management, it is with great excitement that I introduce the first issue of Volume 8. 2019 has lots of interesting things to be excited for; new projects, new ideas and, of course, more excellent content from all of our authors. However, before we start this new period I would like to look back over the past year and our 2018 highlights.2018 was a year of change for the editorial team at Lung Cancer Management with new faces starting and the journal growing. One of the biggest changes is yet to come with our acceptance to PubMed Central; currently in the final stages of the process, we hope to have all content from the past 2 years and onwards available to search through PubMed in the near future. This is a huge step and can only be beneficial in increasing the reach of the articles we publish.Content highlights of 2018The standard of content that we publish has remained high. This is due to both our authors and our reviewers who utilize our peer review and revisions policy to ensure all work is at its best.The most-read article of 2018 also happens to be our most-read article ever published. The research team from Allegheny Health Network Cancer Institute (PA, USA) discusses the use of stereotactic body radiotherapy for early stage lung cancer and outcomes following its use in biopsy-proven and empirically treated lesions [1]. Watch this space as the authors have written not one but two follow-up articles to this piece, hopefully each proving as successful as the last.Another 2018 article hitting our most read list is from our Editorial Board member Antonio Rossi and colleague Lucia Anna Muscarella (Casa Sollievo della Sofferenza Hospital, Italy), commenting on the presence of the NRG1 gene in cases of non-small-cell lung cancer [2].Looking at the use of imaging methods for staging NSCLC, Vasiliki-Konstantina I Gkogkozotou and the team from the University of Athens (Athens, Greece) investigate the use of PET/CT and brain MRI in detecting the different stages of the cancer in patients, concluding that a combination of the imaging techniques can increase accuracy in staging and may help in reducing avoidable thoracotomies and lower morbidity rates [3].Editorial boardUnfortunately, 2018 saw the loss of our long-term editor-in-chief, Dr David Sugarbaker, who passed away last August. The legacy he leaves behind is great and he will long be remembered as a pioneer in the treatment of mesothelioma. He completed the first lung transplant in the state of Massachusetts, developed innovative multimodality therapies and pioneered the technique of extrapleural pneumonectomy. His work will continue through the mesothelioma program he started during his time at Baylor College of Medicine, serving patients and families from around the world. Our sympathies go out to his family and colleagues; he will be sorely missed.To the rest of our Editorial Board, we thank them for their continued input, be it in an ambassadorial, advisory or authorship role, and we look forward to working together in the coming year.Article outreachTo help further spread the work we publish, we continue to utilize the power of social media and share new work through platforms such as Twitter to ensure articles can be shared with the largest possible audience; if you do not already, we welcome you to follow us on Twitter (@fsglmt). In using social media it is our aim to reach all relevant stakeholders in the field of lung cancer management – including researchers, clinicians, charities, patients, academics/educators and patient advocates, just to mention a few.Our partnership with the site Oncology Central [4] continues, giving authors the opportunity to put their work on the Oncology Central website and be seen by its wide readership base. Registration to Oncology Central is free and allows you to keep up to date with the latest developments in cancer research via unparalleled free access to the latest news, opinion, peer-reviewed journal articles, multimedia and exclusive content.ConclusionOur readers remain central to the success of our journal and we welcome any feedback. Please do not hesitate to contact us with any suggestions for what you would like to see featured or any article proposals of your own. We welcome a wide range of unsolicited article proposals so please do get in touch for more information.I would like to finish by once again thanking all of the authors and reviewers who helped to make Volume 7 possible; we hope to continue to build on this success and look forward to another great year.Financial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/References1 Wegner RE, Ahmed N, Hasan S, Schumacher LY, Van Deusen M, Colonias A. SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions. Lung Cancer Manag. 7(1), LMT01 (2018).Link, CAS, Google Scholar2 Muscarella LA, Rossi A. NRG1: a cinderella fusion in lung cancer? Lung Cancer Manag. 6(4), 121–123 (2018).Link, Google Scholar3 Gkogkozotou VI, Gkiozos IC, Charpiduo AG. PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost–effectiveness. Lung Cancer Manag. 7(2), LMT02 (2018).Link, CAS, Google Scholar4 Oncology Central. www.oncology-central.com.Google ScholarFiguresReferencesRelatedDetails Vol. 8, No. 1 Follow us on social media for the latest updates Metrics History Received 21 November 2018 Accepted 21 November 2018 Published online 20 December 2018 Published in print February 2019 Information© 2018 Future Medicine LtdFinancial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/PDF download

International Journal of Endocrine OncologyVol. 6, No. 1 ForewordOpen AccessWelcome to Volume 6 of International Journal of Endocrine OncologyJennifer StraitonJennifer Straiton*Author for correspondence: E-mail Address: j.straiton@future-science.com Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UKPublished Online:12 Feb 2019https://doi.org/10.2217/ije-2018-0005AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit As the new Editor for International Journal of Endocrine Oncology, it is with great excitement that I introduce the first issue of Volume 6. 2019 has lots of interesting things to be excited about; new projects, new ideas and, of course, more excellent content from all of our authors. The start of our new Journal Watch series will help to broaden the range of topics we are able to publish, increasing our coverage of the latest research in the field.However, before we start this new period, I would like to look back over the past year and our highlights from 2018.Content highlights of 2018The standard of content that we publish has remained high. This is due to both our authors and reviewers who utilize our peer review and revisions policy to ensure all work is at its best. We have received a variety of article types from an international range of authors, each piece providing novel, interesting and exciting developments in the field of endocrine oncology management.Our most-read article of 2018 also happens to be our most-read article of all time. The original research study from Jasmine Shell and the team from the National Cancer Institute (MD, USA) investigated the use of 68-gallium DOTATATE PET-CT imaging in symptomatic patients with suspected neuroendocrine tumors though negative anatomic imaging [1]. Their study suggested the validity of using this imaging technique for determining a diagnosis in difficult cases as well as the benefit of utilizing this information to guide future treatment.Another 2018 article hitting the most-read list is a review from Kristin Long and Rebecca Sippel, from the University of Wisconsin (WI, USA), that discussed treatments for parathyroid carcinoma, both current and future [2]. With surgery currently being the most common method of treatment, the authors advised on the importance of collaborative research to improve early recognition methods as well as to identify novel adjuvant therapies.An editorial authored by Martyn Caplin of University College London (London, UK) introduced lutetium (177Lu) oxodotreotide following its recent approval in Europe for the treatment of gastroenteropancreatic neuroendocrine tumors [3]. This approval has provided a new therapy option for these traditionally difficult-to-treat tumors and is suggested to improve quality of life, showing a reduced risk of progression or death relative to previously used treatments.Editorial BoardTo our Editorial Board, we thank you for your continued input, be it in an ambassadorial, advisory or authorship role. Led by our Senior Editors Electron Kebebew and Karel Pacak (both of the National Cancer Institute, MD, USA), our international board provides valuable assistance and advice that facilitates the publication process; we look forward to working together in the coming year.On this note, if you are interested in joining our advisory board or wish to provide feedback or suggestions for the journal, please do not hesitate to get in touch; we value any and all input that can contribute to the growth and development of the journal.Article outreachTo help further spread the work we publish, we continue to utilize the power of social media and share new work through platforms such as Twitter to ensure articles can be shared with the largest possible audience; if you do not already, we welcome you to follow us on Twitter (@fsgije). In using social media it is our aim to reach all relevant stakeholders in the field of endocrine oncology including researchers, clinicians, charities, patients, academics/educators and patient advocates, just to mention a few.Our partnership with the site Oncology Central [4] continues, giving authors the opportunity to put their work on the Oncology Central website and be seen by its wide readership base. Registration to Oncology Central is free and allows you to keep up to date with the latest developments in cancer via unparalleled free access to the latest news, opinion, peer-reviewed journal articles, multimedia and exclusive content.ConclusionOur readers remain central to the success of our journal and we welcome any feedback. Please do not hesitate to contact us with any suggestions for what you would like to see featured or any article proposals of your own. We welcome a wide range of unsolicited article proposals so please do get in touch for more information.I would like to finish by once again thanking all of the authors and reviewers who helped to make Volume 5 possible; we hope to continue to build on this success and look forward to another great year.Financial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/References1 Shell J, Keutgen XM, Millo C et al. 68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor. Int. J. Endocr. Oncol. 5(1), IJE04 (2018).Link, CAS, Google Scholar2 Long KL, Sippel RS. Current and future treatments for parathyroid carcinoma. Int. J. Endocr. Oncol. 5(1), IJE06 (2018).Link, CAS, Google Scholar3 Caplin M. The recent European approval of lutetium (177Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors. Int. J. Endocr. Oncol. 5(2), IJE09 (2018).Link, CAS, Google Scholar4 Oncology Central. www.oncology-central.com.Google ScholarFiguresReferencesRelatedDetails Vol. 6, No. 1 Follow us on social media for the latest updates Metrics History Received 11 December 2018 Accepted 12 December 2018 Published online 12 February 2019 Published in print March 2019 Information© 2019 Future Medicine LtdFinancial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/PDF download

Breast Cancer ManagementVol. 8, No. 1 ForewordOpen AccessWelcome to Volume 8 of Breast Cancer ManagementJennifer StraitonJennifer Straiton*Author for correspondence: E-mail Address: j.straiton@future-science.com Future Medicine Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UKPublished Online:12 Feb 2019https://doi.org/10.2217/bmt-2018-0019AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit As the new Editor for Breast Cancer Management, it is with great excitement that I introduce the first issue of Volume 8. 2019 has lots of interesting things to be excited for; new projects, new ideas and, of course, more excellent content from all of our authors. The return of our Journal Watch series will help to widen the range of topic areas that we are able to publish, increasing our coverage of the latest information in the field. We have recently been accepted for listing on the Directory of Open Access Journals, something that can only be beneficial in increasing the reach of the articles we publish.However, before we start this new period I would like to look back over the past year and our highlights from Volume 7 and 2018.Content highlights of 2018The standard of content that we publish has remained high. This is due to both our authors and our reviewers who utilize our peer review and revisions policy to ensure all work is at its best. We have received a variety of article types from authors across the world, each providing novel perspectives, as well as interesting and exciting developments in the fields of breast cancer diagnosis and treatment.The most-read article from Volume 7 is a review that also happens to be the most-read article that has ever been published in the journal. In this article, Kimberly Corbin and Robert Mutter, both of the Mayo Clinic (MN, USA), discussed the use of proton beam therapy for treatment of early-stage and locally advanced breast cancer [1]. The ongoing research into this novel treatment shows its promise for various clinical applications and highlights its potential for reducing side effects relative to current treatments. However, as with any new technique, there are multiple challenges to overcome before its clinical use. Further research is needed to establish the future for proton beam therapy and its role in breast cancer therapies.Our reviews have proved particular popular in 2018, with two more making it into our list of most-read articles. Leonie Voorwerk, Marije Kat and Marleen Kok from The Netherlands Cancer Institute Amsterdam (The Netherlands) reviewed the future for biomarkers in predicting an individual's response to immunotherapy [2]. Looking at the breast tumor microenvironment, as well as the putative biomarkers of other tumor types, the team discussed the factors that can guide future studies investigating the possibility of introducing personalized immunotherapy to clinical practice. A second review, written by Jennifer Zocca et al. (Maiden Lane Medical, NY, USA), gives a review of advances in pain management for breast cancer patients as well as potential future directions [3]. With mortality decreasing, maintaining quality of life is a key issue with multiple methods available although, as the authors concluded, more work is needed in this area to improve efficacy of therapies.Editorial boardTo our Editorial board, we thank you for your continued input, be it in an ambassadorial, advisory or authorship role. Led by our Senior Editors J Michael Dixon (University of Edinburgh, UK) and V Craig Jordan (MD Anderson, TX, USA) our international board provides valuable assistance and advice that facilitates the publication process; we greatly look forward to working together in the coming year.On this note, if you are interested in joining our advisory board or wish to provide feedback or suggestions for the journal, please do not hesitate to get in touch; we value any and all input that can contribute to the growth and development of the journal.Article outreachTo help further spread the work we publish, we continue to utilize the power of social media and share new work through platforms such as Twitter to ensure articles can be shared with the largest possible audience. If you do not already, we welcome you to follow us on Twitter (@fsgbmt). In using social media, it is our aim to reach all relevant stakeholders in the field of breast cancer management, including researchers, clinicians, charities, patients, academics/educators and patient advocates, just to mention a few.Our partnership with the site Oncology Central [4] continues, providing authors with the opportunity to put their work on the Oncology Central website and be seen by its wide readership base. Registration to Oncology Central is free and allows you to keep up-to-date with the latest developments in cancer via unparalleled free access to the latest news, opinion, peer-reviewed journal articles, multimedia and exclusive content.ConclusionOur readers remain central to the success of our journal and we welcome any feedback. Please do not hesitate to contact us with any suggestions of what you would like to see featured or any article proposals of your own. We welcome a wide range of unsolicited article proposals so please do get in touch for more information.I would like to finish by once again thanking all of the authors and reviewers who helped to make Volume 7 possible; we hope to continue to build on this success and look forward to another great year.Financial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/References1 Corbin KS, Mutter RW. Proton therapy for breast cancer: progress & pitfalls. Breast Cancer Management. 7(1), BMT06 (2018).Link, CAS, Google Scholar2 Voorwerk L, Kat M, Kok M. Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management. 7(1), BMT05 (2018).Link, CAS, Google Scholar3 Zocca J, Valimahomed A, Yu J, Gulati A. A review of recent advances in the management of breast cancer related pain. Breast Cancer Management. 7(2), BMT08 (2018).Link, CAS, Google Scholar4 Oncology Central. www.oncology-central.com.Google ScholarFiguresReferencesRelatedDetails Vol. 8, No. 1 Follow us on social media for the latest updates Metrics History Received 11 December 2018 Accepted 12 December 2018 Published online 12 February 2019 Published in print March 2019 Information© 2019 Future Medicine LtdFinancial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/PDF download

International Journal of Hematologic OncologyVol. 8, No. 1 ForewordOpen AccessWelcome to Volume 8 of the International Journal of Hematologic OncologyJennifer StraitonJennifer Straiton Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UKSearch for more papers by this authorPublished Online:26 Feb 2019https://doi.org/10.2217/ijh-2018-0012AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit As the new Editor for the International Journal of Hematologic Oncology, it is with great excitement that I introduce the first issue of Volume 8. The year 2019 has lots of interesting things to be excited about; new projects, new ideas and, of course, more excellent content from all of our authors. The return of our Journal Watch series will help to broaden the range of topics we are able to publish, increasing our coverage of the latest information in the field.However, before we start this new period I would like to look back over the past year and our highlights from 2018.The year 2018 was a year of change for the editorial team at International Journal of Hematologic Oncology with new faces starting and the journal gaining recognition. Our presence on PubMed Central has been a huge help in widening our audience and increasing the reach of the articles we publish.Content highlights of 2018The standard of content that we publish has remained high. This is due to both our authors and our reviewers who utilize our peer review and revisions policy to ensure all work is at its best. We have received a variety of article types from an international range of authors, each piece providing novel, interesting and exciting developments in the field of hematologic oncology management.The most-read article of 2018 also happens to be our most-read article ever published. Yazeed Sawalha and Anjali Advani from the Taussig Cancer Institute (OH, USA) reviewed the management of acute lymphoblastic leukemia in older generations, discussing the current approaches and the challenges faced by those in this field [1]. Pointing out the poor prognosis for this age group, they stressed the need for more research in the area.Another 2018 article that has hit our most-read list is an editorial from Pratap Neelakantan and Adam Mead, both of the University of Oxford (UK), who described the history of chronic myeloid leukemia and how treatments have developed through the last 5000 years [2]. Remaining hopeful, they ended on a positive note, suggesting that if advancements continue at this rate then a cure could be in sight.We have also published several original research articles; one of our highlights is from the Harbin Institute of Hematology & Oncology (China), which provides an observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia [3]. This form of leukemia often has a poor outcome in this population group so this study from Ma et al. could help in providing reference material when determining the course of treatment.Editorial BoardTo our Editorial Board, we thank you for your continued input, be it in an ambassadorial, advisory or authorship role. Led by our Senior Editor Michele Baccarani (University of Bologna, Italy), our international board provides valuable assistance and advice that facilitate the publication process; we look forward to working together in the coming year.On this note, if you are interested in joining our advisory board or wish to provide feedback or suggestions for the journal, please do not hesitate to get in touch; we value any and all input that can contribute to the growth and development of the journal.Article outreachTo help further spread the work we publish, we continue to utilize the power of social media and share new work through platforms such as Twitter to ensure articles can be shared with the largest possible audience; if you don't already, we welcome you to follow us on Twitter (@fsgijh). In using social media it is our aim to reach all relevant stakeholders in the field of hematologic oncology – including researchers, clinicians, charities, patients, academics/educators and patient advocates, just to mention a few.Our partnership with the site Oncology Central [4] continues, giving authors the opportunity to put their work on the Oncology Central website and be seen by its wide readership base. Registration to Oncology Central is free and allows you to keep up to date with the latest developments in cancer via unparalleled free access to the latest news, opinion, peer-reviewed journal articles, multimedia and exclusive content.ConclusionOur readers remain central to the success of our journal and we welcome any feedback. Please do not hesitate to contact us with any suggestions for what you would like to see featured or any article proposals of your own. We welcome a wide range of unsolicited article proposals so please do get in touch for more information.I would like to finish by once again thanking all of the authors and reviewers who helped to make Volume 7 possible; we hope to continue to build on this success and look forward to another great year.Financial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/References1 Sawalha Y, Advani AS. Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int. J. Hematol. Oncol. 7(1), IJH02 (2018).Link, CAS, Google Scholar2 Neelakantan P, Mead A. The transformative journey of chronic myeloid leukemia. Int. J. Hematol. Oncol. 7(1), IJH07 (2018).Link, CAS, Google Scholar3 Ma J, Liu T, Jin J et al. An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia. Int. J. Hematol. Oncol. 7(2), IHJ06 (2018).Link, Google Scholar4 Oncology Central. www.oncology-central.com.Google ScholarFiguresReferencesRelatedDetails Vol. 8, No. 1 Follow us on social media for the latest updates Metrics History Received 10 December 2018 Accepted 11 December 2018 Published online 26 February 2019 Published in print February 2019 Information© 2019 Future Medicine LtdFinancial & competing interests disclosureJ Straiton is an employee of Future Science Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.Open accessThis work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/PDF download